25 novembre 2016
Assemblée Générale
25 novembre 2016



Conclusion d’un accord de licence avec BIOPROPERTIES Australie.

VitamFero and Bioproperties enter an agreement to complete the development of VitamFero’s animal toxoplasmosis vaccine Angers, France, September 2, 2015 Melbourne, Victoria, Australia, September 3, 2015 VitamFero (FR) and Bioproperties (AU) announce the execution of an exclusive, worldwide license, codevelopment and distribution agreement aiming to complete the development of VitamFero’s proprietary animal toxoplasmosis vaccine in Bioproperties’ facilities in Sydney, Australia. Through close cooperation between the partners, VitamFero will transfer its veterinary live, attenuated vaccine technology to Bioproperties who will take charge of manufacturing and continue development up to drug registration and launch in main markets. First market approval of an ovine toxoplasmosis vaccine is expected to occur in 2019.